Issue 4   |  30 Jun 2021 


Study Overview
The TRACK trial will evaluate whether a small dose of rivaroxaban, a blood-thinning medication, would reduce cardiovascular death or major cardiovascular events in patients with advanced stages of chronic kidney disease.



Progress Updates

To remain up to date on site status, visit;

Below figures are as of 29 Jun 2021.


Important Study Updates


1. Clarification - Prosthetic heart valve exclusion criterion

There has been a change to Exclusion Criteria #1 which currently states in the protocol: 'Mechanical/prosthetic heart valve'. Please see clarification in red below.
This update to the Exclusion Criteria will be part of the next protocol amendment.


2. Collection of COVID-19 vaccination status

Going forward, COVID-19 vaccination status data will be collected in the Concomitant Medication form in the eCRF.


New TRACK Website Resources

website has had some new additions:

  • New 'Frequently Asked Questions' page
  • New page for Patient Alert Card and Cheat Sheet which contains guides for Eligibility and SAE reporting
  • New online training videos


IBM Training Database Passwords

The passwords for the TRACK training database in IBM have been updated.
Upon signing in, please remember to untick the 'Show Live Studies' checkbox so that the 'TRACK Training' database can appear.